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Abstract
Background: Retinoblastoma, a prototype of hereditary cancer, is the most common intraocular
tumour in children and potential cause of blindness from therapeutic eye ablation, second tumours
in germ line carrier's survivors, and even death when left untreated. The molecular scanning of RB1
in search of germ line mutations lead to the publication of more than 900 mutations whose
knowledge is important for genetic counselling and the characterization of phenotypic-genotypic
relationships.
Results:  A searchable database (RBGMdb) has been constructed with 932 published RB1
mutations. The spectrum of these mutations has been analyzed with the following results: 1) the
retinoblastoma protein is frequently inactivated by deletions and nonsense mutations while
missense mutations are the main inactivating event in most genetic diseases. 2) Near 40% of RB1
gene mutations are recurrent and gather in sixteen hot points, including twelve nonsense, two
missense and three splicing mutations. The remainder mutations are scattered along RB1, being
most frequent in exons 9, 10, 14, 17, 18, 20, and 23. 3) The analysis of RB1 mutations by country
of origin of the patients identifies two groups in which the incidence of nonsense and splicing
mutations show differences extremely significant, and suggest the involvement of predisposing
ethnic backgrounds. 4) A significant association between late age at diagnosis and splicing mutations
in bilateral retinoblastoma patients suggests the occurrence of a delayed-onset genotype. 5) Most
of the reported mutations in low-penetrance families fall in three groups: a) Mutations in regulatory
sequences at the promoter resulting in low expression of a normal Rb; b) Missense and in-frame
deletions affecting non-essential sequence motifs which result in a partial inactivation of Rb
functions; c) Splicing mutations leading to the reduction of normal mRNA splicing or to alternative
splicing involving either true oncogenic or defective (weak) alleles.
Conclusion: The analysis of RB1 gene mutations logged in the RBGMdb has shown relevant
phenotype-genotype relationships and provided working hypothesis to ascertain mechanisms
linking certain mutations to ethnicity, delayed onset of the disease and low-penetrance. Gene
profiling of tumors will help to clarify the genetic background linked to ethnicity and variable
expressivity or delayed onset phenotypes.
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Background
Retinoblastoma (MIM# 180200), a rare embryonic neo-
plasm of retinal origin, is the most common intraocular
tumor in children, with a relative incidence of 3% of all
pediatric tumors. Although current therapeutic strategies
have led to dramatic improvement of individual progno-
sis, retinoblastoma is still life-threatening when leaved
untreated or in cases of late diagnosis, a condition of con-
cern in developing countries [1]. The frequency estimates
of retinoblastoma in different populations range between
1:34.000 and 1:10.000 live-born, with the most reliable
figures between 1:28.000 and 1:15.000. An increasing
incidence observed in recent studies can result from more
complete ascertainment and also from population-genetic
reasons, due to the increased survival of retinoblastoma
patients [2]. Most of the clinical phenotypes can be
explained by the double mutational inactivation of the
retinoblastoma susceptibility gene [3], the prototype
tumor suppressor gene that controls cell cycle progression
[4]. However, additional mutations in apoptosis signaling
may well be involved in tumor development [5], a
hypothesis that has been in the cell-of-origin studies in
mice [6]. In addition, a detailed analysis of the relations
between genotype and phenotypic expression suggest that
the hereditary retinoblastoma has features of a complex
trait [7]. In the hereditary form of the disease, a germ line
mutation is transmitted as a high penetrance (90%) auto-
nomic dominant trait, resulting in a 45% risk in offspring
of patients with hereditary retinoblastoma; the second
inactivating mutation occurs in retinal cell precursors [8].
Most of these patients have bilateral retinoblastoma and a
mean age at diagnosis of 12 months. In the non-heredi-
tary form of the disease, both inactivating events occur
during somatic development of retinal cells and result in
the relatively late onset of a single tumor in one eye [9].
However, nearly 15% of the unilaterally affected patients
have germ line RB1 mutations, representing a 45% risk for
their offspring, and these patients cannot be clinically dis-
tinguished from patients with true somatic unilateral
retinoblastoma, who present a negligible risk for siblings
and offspring. Taking these situations together, the hered-
itary form represents nearly 50% of all the retinoblastoma
patients, according to recent epidemiological figures [10].
The presence of RB1  germ line mutations confers an
increased risk for development of second primary tumors
in the survivors of hereditary retinoblastoma, with a
cumulative incidence of 22% at the age of 25 years. Most
of these second tumors were osteosarcomas (37.0%),
other sarcomas (16.8%) and melanomas (7.4%), while
brain tumors (4.5%), leukemia (2.4%) and non-Hodkin
lymphomas (1.6%) were less frequent [11]. In addition,
hereditary retinoblastoma survivors have a lifetime risk of
developing common epithelial cancers [12].
The development of sensitive and reliable genetic tests to
detect RB1 mutations has greatly improved the identifica-
tion of carriers, facilitating accurate genetic counseling. In
addition, the detection of children at risk among siblings
would obviate the need for many routine examinations
and potentially decrease the economic impact of the dis-
ease [13]. Attempts by several groups to define the muta-
tions resulting in the inactivation of the RB1  gene in
retinoblastoma have led to the identification of a broad
spectrum of mutations. To date, the most comprehensive
report of RB1 mutations corresponds to Lohman's data-
base [14] which contains 228 different mutations and 130
recurrences. In this article we describe an up-dated,
searchable database containing 500 distinct somatic or
germ line RB1 mutations and more than 400 recurrences
that we have retrieved from publications. In addition, we
analyze the spectrum of RB1 mutations, with emphasis in
molecular epidemiology and phenotype-genotype rela-
tionships. This information is important for the develop-
ment of rapid procedures to detect mutations in patients
and also to understanding the molecular mechanisms
leading to tumors with different degrees of penetrance or
expressivity.
Results and discussion
The scope of the database of RB1 gene mutations (RBG-
Mdb) is to retrieve and arrange data from the literature in
a flexible and standardized electronic format as described
in methods. In its present version, it contains 932 entries
extracted from 68 articles referred in Additional File 1,
together with the number of mutations they contribute
and the country of origin of the reporting group. Out of
these entries, 753 correspond to germ line mutations, 155
are somatic mutations in retinoblastoma patients and 24
correspond to RB1  somatic mutations found in other
tumors. The distribution of these mutations in different
retinoblastoma patient is shown in Table 1. These figures
cannot be considered representative of the true incidence
of retinoblastoma phenotypes, since most germ line stud-
ies were carried out in bilateral retinoblastoma patients
and mutation analysis were performed in a limited
Table 1: Distribution of germ line and somatic RB1 mutations by 
phenotype of the patients.
Germ line Somatic Total
Bilateral sporadic 424 24 448
Bilateral familiar 99 99
Low penetrance 27 27
Unilateral sporadic 52 131 183
Unilateral familiar 6 6
Not reported 145 145
Total 753 155 908BMC Genetics 2005, 6:53 http://www.biomedcentral.com/1471-2156/6/53
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amount of unilateral tumor samples. The database also
gives information about the sex of the patient (140
entries) and the age at diagnosis or treatment (258
entries).
Type of mutation
The RBGMdb contains 500 distinct mutations and 433
recurrences (see Table 2). Most of the 932 entries (42 %)
correspond to nonsense (NS) point mutations. This figure
is reduced to 18% of the sample when the 302 recurrent
NS are omitted. In this case, the proportion of NS muta-
tions is closer, although significantly different, from the
data logged in the Human Gene Mutation Database [15],
which gives information of more than 46000 mutations
in human disease. In contrast to the high recurrence of NS
mutations in retinoblastoma (70% of the total recur-
rences), small insertions, deletions or complex ins_del
(ins/del) show a low recurrence and represent a high pro-
portion (48%) of the 500 distinct RB1 mutations; this fig-
ure is much higher than the data in HGMD. Splicing
mutations in RB1 have a moderate (19%) recurrence and
represent twice as much of the proportion of the distinct
SP mutations found in HGMD. On the contrary, MS RB1
mutations are very low (10% of the total) as compared
with the 50% given in HGMD.
Hot spots of RB1 gene mutations
As shown in Figure 1, RB1 mutations are scattered along
the genomic sequence, but also accumulate in discrete
spots of high recurrence, comprising twelve nonsense
mutations, three affecting splicing sites and two missense.
These results confirm and extend previous observations
[13,14] with new hot spots and higher recurrence figures.
Most of the recurrences (270 out of 341, 79%) correspond
to C to T transitions in eleven CGA-arginine codons, in
exons 8, 10, 11, 14, 15, 17, 18 and 23 (see Additional File
2), but no mutations were found in three other CGA
codons, located in exons 1 and 27. It is generally admitted
that the hyper mutability of CGA codons depends on the
methylated status of CpG dinucleotides and the spontane-
ous deamination of 5 methyl cytosine to thymidine [16].
In four of the mutated CGA codons (R251 and R255 in
exon 8, R451 and R455 in exon 14) a high frequency of
constitutive methylation (see Additional File 2) has been
demonstrated and it is assumed that constitutive hyper
methylation would also be present in the other CGA hot
spots [17]. The absence of mutations at the CGA codon
(R7) in exon 1, whose predicted consequence would be a
short and inactive peptide, fits in this model since this
codon is part of an unmethylated CpG island in the RB1
promoter [18]. On the other hand, the absence of muta-
tions in two highly methylated CGA codons (R908 and
R910) in exon 27 is expected, in view of the fact that muta-
tions in the last RB1 exon are not oncogenic [18]. The
same argument can apply to the absence of C>T muta-
tions in the highly methylated CpG codons in position
451 (CGC), 855 (AGC), 857 (CGT) and 876 (CGC) in
RB1 gene [17], whose predicted outcome would be non
oncogenic missense or silent amino acid substitutions
(R451R, S855S, R857C and R876R).
In this sense it is worth to mention the different fate of
three CGG-codons in RB1 gene: two of unknown methyl-
ated status in exon 20, comprising the highly recurrent
R661W (20 mutations as shown in Additional File 2) and
R656W (1 mutation); the third, in exon 8 (R262) is fre-
quently methylated although no mutations have been so
far observed. In these cases, the differences in mutability
cannot be explained by the methylation status not by dif-
ferences in tumorogenity (oncogenity), since both R656W
and R661W lie in the folded and hydrogen-bond rich
structural domain of the A-B interface, together with other
missense mutations [19]. Alternatively, the hyper muta-
bility found in R661 can be explained by neighboring-
nucleotide effects (TCGG in R661 versus ACGG in R656
and R 262) and the known differences in mutability of
these tetranucleotides [20]. In the case of other non-CpG
hot spots in RB1 gene, such as the nonsense E137X and
the three splicing mutations affecting the first invariant
nucleotide in introns 6, 12 and 19, the presence of short
quasi-repeat sequences could be documented (see Addi-
tional file 2). These sequence motifs would favor replica-
tion errors such as misinsertions or misalignments
leading to base substitution or single-base frameshift with
Table 2: Number of entries by mutation type as compared with HGMD data. Statistical analysis of distinct RBGMdbDB vs. HGMD 
using χ2 test.
All mutations Distinct mutations Distinct mutat.
RBGMdb % RBGMdb % HGMD % χ2 test
Nonsense 395 42.4 93 18.6 5840 12.6 P < 0.0001
Missense 81 8.7 50 10.0 22940 49.6 P < 0.0001
Splicing 194 20.8 111 22.2 4771 10.3 P < 0.0001
Regulatory 7 0.7 5 1.0 626 1.4 P = 0.6267
Small ins/del 255 27.3 241 48.2 12076 26.1 P < 0.0001
Total 932 500 46253BMC Genetics 2005, 6:53 http://www.biomedcentral.com/1471-2156/6/53
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the mismatch repair machinery [21]. Although this DNA
environment offers an attractive explanation for the pres-
ence of hot spots in non CpG sites, no preponderance of
direct or inverted repeats has been observed in the spec-
trum of single-base-pair substitutions logged in the
HGMD [22]. However, the HGDM only includes distinct
mutations and therefore an association of repeated
sequence motifs with recurrent mutations cannot be
excluded.
Mutational spectrum of RB1 by exon
In addition to hot spots, frameshift and point mutations
leading to amino acid substitutions or splicing are scat-
tered along the retinoblastoma cDNA and non-coding
adjacent splicing sites, giving the spectrum of mutations
shown in Figure 2. With the exception of exons 5, 14, 15,
24, 25 and the non-mutated exons 26 and 27, frameshift
mutations are randomly distributed through the RB1 cod-
ing sequence. Splicing mutations are also evenly distrib-
uted, but show preference for intronic sequences adjacent
to exons 6, 12, 16, 17, 19 and 24; three of them are asso-
ciated to the above described recurrences (see Figure 1).
The exonic distribution of point mutations correspond to
the hot spots already described in Figure 1. It is worth to
mention that most missense substitutions (60 %) are
located in cyclin box B, underlined by exons 19 to 21. The
spectrum of RB1 mutations by exon has important impli-
cations in the mutational screening of retinoblastoma
patients, which might benefit from the sequential analysis
employing quantitative multiplex PCR (QM-PCR) meth-
Mutational hot spots in RB1 Figure 1
Mutational hot spots in RB1. The number of entries found for each mutation is represented against the modified genomic 
nucleotide. Description of high recurrent mutations is shown.BMC Genetics 2005, 6:53 http://www.biomedcentral.com/1471-2156/6/53
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odology to detect frameshift mutations[23,24] and PCR-
sequencing of highly mutated exons 9, 10, 14, 17, 18, 20
and 23.
Spectrum of RB1 gene mutations by country of origin
The distribution of mutations logged in the RBDB by type
and country of origin (shown in Additional File 3) allows
establishing the two different spectra of RB1 gene muta-
tions shown in Figure 3. In certain South American coun-
tries (Argentina, Brazil, Colombia, Cuba and Ecuador) as
well as in Russia, United Kingdom and Germany,
amounting to a total of 392 mutations (group A in Figure
3), the incidence of NS and SP mutations is respectively
higher (p = 0.017) and lower (P = 0.003) than in the
grand total of 925 mutations. On the contrary, in United
States, France and Spain (group B in Figure 3) the inci-
dence of NS is lower (P = 0.022) and that of SP is higher
(P = 0.023) than the average found for all mutations. The
differences in incidence of NS (50.8 and 35.4%, P =
0.0002) and SP (13.7 and 27.9%, P < 0.0001) mutations
between groups A and B respectively, are extremely signif-
icant and suggest the presence of predisposing ethnic
backgrounds. Since most NS mutations in RB1 (80% in
RBGMdb) correspond to C>T transitions, origin of a G: T
mispair, and the eukaryotic mismatch (MMR) complex
MSH2–MSH6 (MIM#120435 and 600678, respectively)
seems to be more efficient in G: T mismatch repair [25], it
is suggested that susceptibility to NS RB1 mutations can
be increased by an imbalance between DNA methylation
vs. mismatch repair (MSH2–MSH6) activities [26].
Age and type of mutations
In correspondence with larger statistical studies [2,9] the
mean age at diagnosis for bilateral and unilateral retino-
blastoma patients in DBRB is of 12.5 and 24.8 months
respectively, and this difference was extremely significant
(P = 0.00006). Similar differences are observed in all but
splicing mutations (Table 3), whose mean age at diagnos-
tic in bilateral and unilateral patients are statistically
indistinguishable. This result, which confirms previous
observations [27], suggests that splicing mutations can be
associated to a delayed onset phenotype. The molecular
basis of this phenotype could be related to mechanisms
considered in low-penetrance splicing mutations.
Low penetrance retinoblastoma
In 27 out of the 133 (20%) familial retinoblastoma
entries in RBGMdb, the presence of unaffected carriers
(reduced penetrance) or unilateral retinoblastoma or
benign retinoma (reduced expressivity) were documented
(see Additional file 4 for a complete description of the
mutations and references). This figure probably represents
an overestimation of the true incidence of the low pene-
trance (LP) phenotype, biased by its notorious scientific
interest. As shown in Table 3, most of the reported muta-
tions associated to LP families (23/28 = 82%) correspond
to MS and SP mutations, with hot spots in g.156713 C>T
(R661W), g.160757T>C (C712R) and g.45867G>T
(IVS6+1G>T). Different mechanisms have been proposed
to explain this rare phenotype, including epigenetic
events, delayed mutation, involvement of a second retin-
oblastoma locus ("three-hit hypothesis") or host resistant
factors. However, most low-penetrance retinoblastoma
can be explained by mutations at the RB1 locus [28].
Mutations affecting regulatory sequences in the RB1 pro-
moter are known to reduce the expression of normal Rb
protein below a threshold level, necessary for tumor sup-
pression functions [29,30]. Missense single-nucleotide
substitutions can, under certain circumstances, partially
inactivate the retinoblastoma function. In the case of the
highly recurrent R661W mutant allele, Otterson et al.
have shown that the mutant retinoblastoma protein has a
temperature-sensitive pocket activity whose reversible
fluctuations may result in the low penetrance phenotype.
Table 3: Age at diagnosis in retinoblastoma patients according to phenotype and type of mutation. Statistical analysis using the 
Welch's unpaired t test.
Phenotype Frameshift Nonsense Missense Splicing SP vs. NS-MS-FS
U n i l a t e r a l 2 1 . 12 6 . 02 3 . 72 6 . 7P  =  0 . 7 2 3 7
Bilateral 9.5 11.8 9.4 19.3 P = 0.0025
A l l 1 2 . 41 5 . 61 6 . 02 1 . 8P  =  0 . 0 0 4 4
Unilateral vs. Bilateral P = 0.0073 P = 0.0147 P = 0.3321
Spectrum of RB1 mutations by exon Figure 2
Spectrum of RB1 mutations by exon. The number of entries 
for each type of mutation is distributed by exon and adjacent 
5' and 3' intronic sequences.BMC Genetics 2005, 6:53 http://www.biomedcentral.com/1471-2156/6/53
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Temperature-sensitive Rb pocket activity may also explain
the low penetrance of C712R and delN480 [31]. In the
case of the large in frame deletions outside the pocket
domain, such as Del: E04 [32] and Del: E24–25 [33],
unessential functions of Rb protein seems to be affected.
After the report of a splicing mutation (c.2211G>A) affect-
ing the last nucleotide of exon 21 [34], a new category of
low-penetrance genotype has been proposed to occur
through alternative splicing mechanisms. In the case
reported by these authors, the RNA analysis showed skip-
ping of exon 21 and a low amount (10%) of normally
spliced RNA (E732E) which can explain the variable
expressivity observed in that family. A similar mechanism
can explain the low-penetrance of other splicing muta-
tions affecting the last exonic nucleotide, such as
c.1331A>G and c.1960G>C. In these cases, the splicing
machinery could alternate between defective missense
splicing (Q443P and V654L, respectively) and inactivat-
ing skipping of exons 13 or 21, both in the pocket box
domain of Rb. In the low-penetrance family studied by
Lefevre et al., a T>C substitution in the polypyrimidine
tract of intron 8 (IVS9-10T>C) was shown to be at the ori-
gin of the in frame deletion of exon 9 giving a defective or
inactive Rb protein lacking 26 amino acids from the N-ter-
minal region. It is also possible that this mutation only
partially affected spliceosome assembly and that the
mutated allele could be in part correctly spliced. While
this alternative splicing mechanism would better explain
the low-penetrance phenotype, no supporting evidence is
available [35]. Similar alternative mechanism could also
explain the low-penetrance of c.2325+5G>A, causing in
frame skipping of exon 22 [36]. In this case, the G>C
transversion makes a slight reduction of the consensus
value of the 5' splice site [37] from 88 to 75 compatible
with the presence of a fraction of correctly spliced mutant
allele.
Alternative splicing mechanisms might also be involved
in the recurrent c.607+1G>T transversion, firstly described
in a low-expressivity and delayed onset phenotype in one
Spanish family [27], and thoroughly analyzed by Klutz et
al [38] in two low-penetrance German pedigrees. These
authors made the interesting observation of a posttran-
scriptional mechanism that reduces the level of the
mutant transcripts (skipping of exon 6 giving a stop
codon in exon 7) when the mutant allele was received
from the father. However this parent-of-origin effect does
not explain the low-penetrance phenotype, since all but
one unaffected carriers have maternally inherited mutant
alleles and high level of expression, while most of the
tumor bearing carriers have paternally inherited mutant
alleles and low level of expression of the mutant allele. In
a search for alternative splicing mechanisms, using the
electronic exon-search facilities at HGMP, we have
observed the presence of a cryptic exon whose usage in
mutant alleles (see Additional File 5) could result in a
defective Rb protein lacking 12 amino acids in the amino
terminal region. Since no evidence of in-frame restoring
mechanisms in lymphoblastoid cell line derived from
unaffected carriers was observed [38], the hypothetical
alternative splicing mechanism should be explored in
retinoblastoma derived cell lines. In the only nonsense
substitution (Q675X) observed in a low-penetrance phe-
notype, the G>T transversion in c.2023 could also activate
a cryptic splicing site involving the stop codon, with the
result of a defective Rb lacking 22 amino acids [39].
Conclusion
The analysis of RB1 gene mutations logged in the RBG-
Mdb has shown relevant phenotype-genotype relation-
ships and provided working hypothesis to ascertain
mechanisms linking certain mutations to ethnicity,
delayed onset of the disease and low-penetrance. In con-
sidering the variable phenotypes associated to low-pene-
trance genotypes (see frequencies in Table 4) Richter et al.
have proposed that unilateral sporadic carriers of these
mutations should be considered the founders of low-pen-
etrance families [23]. The same observation has led to
Lohmann et Galli to suggest that the hereditary retino-
blastoma has features of a complex trait [7]. In order to
clarify these alternatives, functional studies should be car-
ried out in order to provide better insights into the pro-
posed mechanisms for low-penetrance mutations. In
addition, gene expression profiling of tumors will help to
clarify the genetic background linked to ethnicity and var-
iable expressivity or delayed onset phenotypes. It will also
be desirable to build up an international retinoblastoma
study group in order to gather high quality information
relevant to molecular studies, prognosis, therapy response
Spectrum of RB1 mutations by country of origin Figure 3
Spectrum of RB1 mutations by country of origin. Distribution 
of mutations in Canada and two groups of nations and statis-
tical comparison with all mutations in RBGMdb. (*) and (**) 
stand for P < 0.05 and 0.01, respectively).BMC Genetics 2005, 6:53 http://www.biomedcentral.com/1471-2156/6/53
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and long-range follow-up of carriers of low-penetrance
mutations.
Materials and methods
Data mining
Primary bibliographic resources were retrieved from Ent-
rez-PubMed, searching for human retinoblastoma (RB1)
mutations. Reprints of all these articles were obtained and
additional articles describing RB1 mutations were picked
up from its reference lists. In addition, all the articles from
the same authors or research group were thoroughly scru-
tinized in order to avoid repetitions of mutations present
in one patient. In all, data from 68 research articles have
been compiled in the data base. These articles, together
with the number of mutation they contributed and the
country of origin of the main research group are supplied
in the Additional file 1.
Description of the flat-file format
All the mutations were thoroughly revised according the
recommended nomenclature for sequence variations [40]
using the genomic sequence GenBank: L11910.1, the
cDNA sequence NCBI: NM_000321.1, and the protein
sequence NCBI: NP_000312.1. The mutations were anno-
tated in a Microsoft Excel data sheet containing 15 col-
umns (Shown in Additional File 6).
Structure and management of the database
To facilitate access to the collected data, we have created
an SQL database and developed an easy to use web inter-
face that provides for simple and complex queries to the
database, allowing to sort results by any field and to pro-
duce both, HTML and PDF reports. The database engine is
based on MySQL [41], a popular, open source DBMS. The
user interface is based on HTML forms and PHP [42]
scripts, with some bits of public Javascript code [43] for
data validation and online help. PDF output is generated
by using the FPDF library [44]. The whole code of the
web-based user interface and SQL schema is publicly
available from the site.
The public interface of RBGMdb is located at EMBnet
Spanish node [45]. As we have already mentioned, it pro-
vides resources for issuing simple queries for records con-
taining a search term, as well as for complex queries where
up to four search terms may be looked up on user-speci-
fied fields each combined with its logical operator.
Searches produce their results as an HTML table with
online help that is displayed whenever the cursor moves
over any field. Results may be further sorted by any field
by just clicking on the field name in the table header. The
user is offered the possibility of generating PDF reports for
download and/or printing at every step of the process. In
addition to the search forms, we have created a submis-
sion form to facilitate the public addition of new data.
This form sends an e-mail to the database coordinator
who effectively acts as supervisor for all new additions.
Restricted access database update forms are also available
for the database coordinator(s) to actually modify the
data in the database.
Computer analysis and statistics
When indicated, normal and mutated RB1 sequences
were analyzed with the programs for exon identification
Table 4: Molecular basis of low penetrance retinoblastoma
Type of mutation Number of LP 
families
Description of mutations and frequency 
a
Functional consequences
Regulatory 3 -198G>A (1/2)
-188G>T (1/2)
-149G>C (1/1)
Low expression of normal Rb protein
MS point mutations 12 R661W (8/20)
C712R (2/5)
W563L (1/1)
R787Q (1/1)
Partial inactivation of Rb protein
Inframe deletion 3 Del:N480 (1/1)
Del:E04
Del: E24–25
Partial inactivation of Rb protein
Splicing 10 607+1G>T (4/11)
862-10T>C (1/1)
539+1delG, del E05 (1/1)
2325+5G>A, del E:22 (1/1)
Q443P/del:E13 (1/1)
V654L/splice (1/2)
E732E/del E:21(1/2)
Alternative splicing and/or unessential exon skipping resulting 
in low expression or partial inactivation of Rb protein
NS point mutation 1 Q675X (1/1) Alternative splicing involving the stop codon
aRatio of mutations found in LP families vs. all mutations in the database is shown in bracketsBMC Genetics 2005, 6:53 http://www.biomedcentral.com/1471-2156/6/53
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available at the Computing Services of UK HUMAN
GENOME MAPPING PROJECT [46]. Statistical signifi-
cance tests used in this study included Chi square and
Fisher exact test for 2 × 2 tables, and the Welch's unpaired
t test and nonparametric Mann-Whitney test for the anal-
ysis of means. Statistical summaries from the Human
Gene Mutation Database (HGMD) were retrieved from
the web.
List of abbreviations used
RBGMdb (Retinoblastoma gene mutation database), LP
(low-penetrance), NS (nonsense), MS (missense), FS
(frameshift), SP (splicing),
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